New RSV vaccine shows promise for seniors in global study
NCT ID NCT06551181
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study tested an experimental RSV vaccine from GSK in over 2,600 adults aged 60 and older, mostly in China and some overseas. The goal was to see if the vaccine produces a strong immune response and is safe. Researchers compared immune responses between Chinese and overseas participants to confirm the vaccine works similarly across populations. The study is complete, and results will help determine if the vaccine can protect older adults from RSV-related respiratory illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Shanghai, Putuo, 200065, China
-
GSK Investigational Site
Shanghai, Putuo, China
-
GSK Investigational Site
Shanghai, Shanghai Municipality, China
-
GSK Investigational Site
Shanghai, 200136, China
-
GSK Investigational Site
Shanghai, 201620, China
-
GSK Investigational Site
Shanghai, 201901, China
-
GSK Investigational Site
Shanghai, China
-
GSK Investigational Site
Espoo, 02230, Finland
-
GSK Investigational Site
Helsinki, 00290, Finland
-
GSK Investigational Site
Kokkola, 67100, Finland
-
GSK Investigational Site
Oulu, 90220, Finland
-
GSK Investigational Site
Seinäjoki, 60100, Finland
-
GSK Investigational Site
Tampere, 33100, Finland
-
GSK Investigational Site
Turku, 20520, Finland
-
GSK Investigational Site
Tokyo, 160-0017, Japan
-
GSK Investigational Site
Elblag, 82-300, Poland
-
GSK Investigational Site
Katowice, 40-282, Poland
-
GSK Investigational Site
Katowice, 40-600, Poland
-
GSK Investigational Site
Krakow, 31-501, Poland
-
GSK Investigational Site
Lodz, 91-363, Poland
-
GSK Investigational Site
Lublin, 20-362, Poland
-
GSK Investigational Site
Sochaczew, 96-500, Poland
-
GSK Investigational Site
Warsaw, 00-215, Poland
-
GSK Investigational Site
Wroclaw, 50-088, Poland
-
GSK Investigational Site
Guri-si, 471-701, South Korea
-
GSK Investigational Site
Incheon, 400-711, South Korea
-
GSK Investigational Site
Seoul, 152-703, South Korea
-
GSK Investigational Site
Ávila, 05071, Spain
-
GSK Investigational Site
Barcelona, 08036, Spain
-
GSK Investigational Site
Burgos, 09006, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Salamanca, 37007, Spain
-
GSK Investigational Site
Valladolid, 47003, Spain
-
GSK Investigational Site
Belfast, BT7 2EB, United Kingdom
-
GSK Investigational Site
Blackpool, FY3 7EN, United Kingdom
-
GSK Investigational Site
Bristol, BS37 4AX, United Kingdom
-
GSK Investigational Site
Cambridgeshire, CB7 5JD, United Kingdom
-
GSK Investigational Site
Eynsham, OX29 4QB, United Kingdom
-
GSK Investigational Site
Hounslow, TW3 3EL, United Kingdom
-
GSK Investigational Site
Witney, OX28 6JS, United Kingdom
Conditions
Explore the condition pages connected to this study.